Taipei Exchange - Delayed Quote TWD

BIONET Corp. (1784.TWO)

72.40
0.00
(0.00%)
At close: 1:30:25 PM GMT+8
Loading Chart for 1784.TWO
  • Previous Close 72.40
  • Open 72.40
  • Bid 72.40 x --
  • Ask 72.60 x --
  • Day's Range 71.80 - 73.50
  • 52 Week Range 57.51 - 162.01
  • Volume 89,812
  • Avg. Volume 254,110
  • Market Cap (intraday) 3.664B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 43.88
  • EPS (TTM) 1.65
  • Earnings Date --
  • Forward Dividend & Yield 0.71 (0.98%)
  • Ex-Dividend Date Sep 19, 2024
  • 1y Target Est --

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived products. BIONET Corp. was founded in 1989 and is based in Taipei City, Taiwan.

www.bionetcorp.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1784.TWO

View More

Performance Overview: 1784.TWO

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1784.TWO
8.93%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
10.91%

1-Year Return

1784.TWO
21.59%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.00%

3-Year Return

1784.TWO
107.69%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
25.08%

5-Year Return

1784.TWO
108.38%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
90.47%

Compare To: 1784.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1784.TWO

View More

Valuation Measures

As of 5/5/2025
  • Market Cap

    3.66B

  • Enterprise Value

    2.18B

  • Trailing P/E

    43.88

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.01

  • Price/Book (mrq)

    2.75

  • Enterprise Value/Revenue

    1.79

  • Enterprise Value/EBITDA

    14.65

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.85%

  • Return on Assets (ttm)

    1.42%

  • Return on Equity (ttm)

    3.39%

  • Revenue (ttm)

    1.22B

  • Net Income Avi to Common (ttm)

    83.7M

  • Diluted EPS (ttm)

    1.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.57B

  • Total Debt/Equity (mrq)

    3.93%

  • Levered Free Cash Flow (ttm)

    -23.02M

Research Analysis: 1784.TWO

View More

People Also Watch